0.80Open0.80Pre Close0 Volume1 Open Interest0.50Strike Price0.00Turnover0.00%IV-5.11%PremiumOct 18, 2024Expiry Date0.87Intrinsic Value100Multiplier20DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.61Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Tempest Therapeutics Stock Discussion
Tempest Therapeutics, a clinical-stage biotechnology firm, recently announced a major milestone in their development of amezalpat (TPST-1120), a promising therapeutic agent for treating first-line unresec...
another good rating for a price target.
I wouldn't complain about 13.00 dollars
I want some of that 47 dollars share price target....lfg
No comment yet